WuXi AppTec

Headlines · 6

1. 2d
   PerturbMind AI launches AlphaCell 1.0 Pro for omics drug discovery

   PerturbMind AI has emerged from stealth, announced angel and angel+ financing totaling tens of millions of yuan, and launched the PerturbSeek digital-life world-model ecosystem. The company released AlphaCell 1.0 Pro, a geometric world model for virtual-cell state and perturbation-trajectory inference. The standard version has 1 billion parameters, with configurable versions ranging from 300 million to 50 billion parameters. PerturbMind AI says the model can support disease-mechanism analysis, target discovery and drug-response modeling. The reports state that its ability to understand complex biological systems still requires continued experimental validation and testing in actual drug-development projects.

   MIT科技评论中文 · 🔥 6
2. 3d
   Chinese mutual funds stay heavily exposed to AI technology stocks

   TMTPost reports that Chinese active equity funds remained heavily concentrated in electronics and communications in Q3 2026, with leading holdings including Zhongji Innolight, Eoptolink and WuXi AppTec. Tianxiang Investment Consulting put their combined heavy-position weight at 51.69%, while Orient Securities and Guosen Securities estimated about 52.02% and 50.6%, respectively, despite a sharp adjustment in technology shares. Orient Securities found that some weight declines were price-driven rather than active selling, while Guosen still reported active underweighting.

   钛媒体 · 🔥 0
3. 3d
   China mutual funds keep AI hardware exposure elevated in Q3

   TMTPost reports that publicly offered funds completed their Q3 disclosures, with the article’s data covering the top 10 A-share holdings across equity and some bond funds but excluding Hong Kong. Electronic companies remained the largest allocation at 33.6%, followed by communications at 13.0%; versus Q2, electronics slipped one percentage point while communications gained two. The analysis also says AI hardware has become a major focus for institutional portfolios, while cautioning that its concentration differs from measures based only on actively managed equity funds.

   钛媒体 · 🔥 0
4. Oct 23
   Verdine weighs AI’s drug-discovery value against capital pressure on biotech

   In a Huxiu interview, Harvard professor Gregory L. Verdine said AI benefits drug discovery by changing researchers’ work rather than replacing them. He also argued that AI offers faster and larger returns, while biotech lacks scale effects, making it harder for biotechnology to compete for venture investment. Verdine said Chinese innovation-drug companies remain focused mainly on best-in-class assets and need more long-term investment in novel targets. Tsinghua University pharmacy dean Qian Feng said overseas licensing has become a financing route for Chinese biotech companies struggling to raise capital domestically.

   虎嗅 AI · 🔥 0
5. Oct 22
   Warp Sciences raises $215M for AI-driven automated chemistry labs

   Kevin Weil has launched Warp Sciences with $215 million in funding led by Lightspeed Venture Partners, valuing the startup at $865 million including the new money, according to Bloomberg and The Next Web. The company plans a US chemistry laboratory where AI designs experiments, robots execute them, and resulting data improves later experiments, initially focusing on molecular-variant synthesis during lead optimization. MIT Technology Review China reports that the lab remains under development and that Warp Sciences has not published turnaround-time, cost or model-performance data.

   The Next Web · 🔥 0
6. Oct 10
   AI drug design is flooding Chinese labs with wet-lab work

   Anthropic's Claude designed 1,320 binding proteins against a dozen targets, which Adaptyv Bio and Twist synthesized and tested; 354 were confirmed to bind, a hit rate near 30% versus the traditional 10%–15%. The article argues that as AI pushes the marginal cost of molecular design toward zero, the first orders flow to lab-service providers: GenScript's AIDD revenue doubled year over year in H1 with gross margins about 20 points above its traditional protein-expression business, while XtalPi posted 803 million yuan in 2025 revenue, tripled and its first full-year profit. Meanwhile Washington is trying to pull early-stage R&D and clinical capacity back onshore via HHS's TrialBlazer plan and the BIOSECURE Act.

   MIT科技评论中文 · 🔥 0

Experience and discussion from the community

Share my WuXi AppTec experienceAsk about WuXi AppTec